Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
August 2005
Revised Date: 
December 2019
  • Treatment of susceptible fungal infections including oropharyngeal and esophageal candidiasis
  • Serious systemic candidal infections
  • Treatment of cryptococcal meningitis
Reconstitution and Stability: 
  • Supplied as a 2 mg/mL solution
  • Store at room temperature
  • Punctured vial stable 7 days at room temperature

- Solutions Compatible: D5W, NS, ringer's lactate

- Additives/Above Cassette Compatible: no information

- Y-site Compatible: acyclovir, cefazolin, dexamethasone, diphenhydramine, ganciclovir, gentamicin, hydrocortisone, KCL, metoclopramide, meropenem, morphine, ondansetron, penicillin G, phenytoin, tobramycin, TPN (amino acids/dextrose), vancomycin, zidovudine

- Incompatible: ampicillin, calcium gluconate, cefotaxime, ceftazidime, cefuroxime, ceftriaxone, clindamycin, diazepam, furosemide, imipenem, pentamidine, piperacillin, ticarcillin, trimethoprim-sulfamethoxazole (if these drugs are given concurrently, flush tubing with normal saline before and after fluconazole)


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct NO
IV Intermittent Infusion

Usual dilution: undiluted (2 mg/mL)
Infusion time: 1-4 hours, for doses greater than or equal to 6 mg/kg/day infuse over 2 -4 hours
Infusion rate: do not exceed 200 mg/hour

IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 3-12 mg/kg/day IV once daily
  • Maximum: 800 mg/day


  • 100-800 mg IV once daily


  • CrCl  21-50 mL/minute:  50% of recommended dose OR extend dosing interval to Q48H
  • CrCl   < 20 mL/minute:   25% of recommended dose OR extend dosing interval to Q72H
  • Hemodialysis: usual dose - give after hemodialysis

- Higher doses may be required for certain fungi (other than candida); cryptococcal meningitis

Potential hazards of parenteral administration: 
  • Nausea, vomiting, abdominal pain, diarrhea
  • Headache, dizziness                              
  • Rash and pruritis
  • Transient elevation of liver function tests
  • Daily dose of fluconazole is the same for oral and IV administration
  • Increased serum concentrations of AST, ALT, alkaline phosphatase, total bilirubin; patients with baseline abnormal liver function tests or who develop abnormal liver function tests during therapy should be monitored for the development of more severe hepatic injury
  • Monitor periodic liver function and renal function tests
  • Monitor patients also on warfarin - increased prothrombin time
  • May decrease clearance of cyclosporin, phenytoin, zidovudine
  • Rifampin increases fluconazole metabolism

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.